Clinical trials: Erythropoietin
Anemia
Safety and Efficacy of Sustained Erythropoietin Therapy
The purposes of this study are to assess safety, efficacy, and subject satisfaction of EPODURE Biopump (an autologous dermal biopump capable of sustained secretion of therapeutic EPO in the body, using a small tissue explant from…
- Trial name
- NCT00542568
- Testing
- EPODURE (dermal Biopump for erythropoietin)
- Where
- 2 sites in Israel
- Volunteers
- 19 people
- Sponsor
- Medgenics Medical Israel Ltd.
Acute Myocardial Infarction
MAGIC Cell-5-Combicytokine Trial
Combination use of darbepoetin and G-CSF will improve left ventricular systolic function in patients with acute myocardial infarction who receive intracoronary infusion of mobilized peripheral blood stem cell in comparison with…
- Trial name
- MAGIC Cell-5 (NCT00501917)
- Testing
- G-CSF with/without darbepoetin, peripheral blood stem cell infusion
- Where
- South Korea
- Volunteers
- 116 people
- Sponsor
- Seoul National University Hospital
Cardiac Surgery
Effect of Preoperative Recombinant Human Erythropoietin on Transfusion Risk in Valvular Heart Surgery
The administration of rhEPO on the one day before cardiac surgery will be effective to decrease the bleeding due to the surgery.
- Trial name
- NCT00939978
- Testing
- rhEPO
- Where
- South Korea
- Volunteers
- 74 people
- Sponsor
- Yonsei University
Aneurysmal Subarachnoid Hemorrhage
Erythropoietin Therapy for Subarachnoid Hemorrhage
ABSTRACT: Delayed ischemic deficits (DID) and strokes caused by low cerebral blood flow (CBF) are major sources of poor outcome following aneurysmal subarachnoid hemorrhage (SAH).
- Trial name
- NCT00140010
- Testing
- erythropoietin beta
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- University of Cambridge
Encephalopathy, Erythropoietin
Erythropoietin for Neonatal Encephalopathy in LMIC (EMBRACE Trial)
One million babies die, and at least 2 million survive with lifelong disabilities following neonatal encephalopathy (NE) in low and middle-income countries (LMICs), every year.
- Conditions
- Encephalopathy, Erythropoietin, Newborn Asphyxia
- Trial name
- EMBRACE (NCT05395195)
- Testing
- Erythropoietin, Supportive neonatal intensive care
- Where
- 10 sites in Bangladesh, India and 1 more
- Volunteers
- 504 people
- Sponsor
- Imperial College London
Anaemia
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease
This study aims to characterize the relationship between dose of GSK1278863 and hemoglobin (Hgb) response in hemodialysis-dependent (HDD) subjects with anemia associated with chronic kidney disease (CKD).
- Trial name
- NCT02019719
- Testing
- GSK1278863
- Where
- 21 sites in Japan
- Volunteers
- 97 people
- Sponsor
- GlaxoSmithKline
Anaemia
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
This is a four-week Phase IIa, randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in approximately 68 subjects with anemia…
- Trial name
- NCT01587898
- Testing
- GSK1278863
- Where
- 55 sites in United States, Canada and 1 more
- Volunteers
- 72 people
- Sponsor
- GlaxoSmithKline
Renal Anemia
A Study of PEG-EPO Injection (CHO Cells) for Maintenance Therapy of Patients With Renal Anemia .
The purpose of the study is to explore the optimal dose and administration of the experimental drug, and to evaluate the safety and efficacy of the drug in patients with renal anemia.
- Trial name
- NCT05629598
- Testing
- Recombinant human erythropoietin injection, Human erythropoietin injection
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Angde Biotech Pharmaceutical Co., Ltd.
Anemia, Chronic Renal Insufficiency
A Study to Evaluate PROCRIT (Epoetin Alfa) for Maintenance Phase Treatment of Patients With Anemia Due to Chronic Kidney Disease (PROMPT)
The purpose of this study is to evaluate the effectiveness and safety of less frequent dosing of PROCRIT (Epoetin alfa) in patients with anemia due to Chronic Kidney Disease (CKD) as assessed by hemoglobin maintenance, adverse…
- Trial name
- NCT00307814
- Testing
- Epoetin Alfa
- Volunteers
- 519 people
- Sponsor
- Ortho Biotech Products, L.P.
Ischemic Cardiomyopathy
Chronic, Low Dose Erythropoetin Beta in Ischemic Cardiomyopathy
The study is testing the hypothesis, that the application of low dose erythropoetin beta (35 I.E./kg BW/week) for 6 months following successful coronary revascularization by PCI improves left ventricular remodeling as assessed by…
- Trial name
- EPOHeart (NCT00568542)
- Testing
- erythropoetin beta
- Where
- 2 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Charite University, Berlin, Germany
Luspatercept, Epoetin
Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for hematological malignancies. Nonetheless, poor graft function remains a life-threatening complication after allo-HSCT.
- Conditions
- Luspatercept, Epoetin, Poor Erythroid Engraftment, Hematological Malignancies
- Trial name
- NCT07636486
- Testing
- Luspatercept, Epoetin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Anemia, Chronic Kidney Disease (CKD)
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
The purpose of this study is to show biosimilarity of HX575 epoetin alfa with the US licensed reference product Epogen®/Procrit® when applied subcutaneously.
- Trial name
- ACCESS (NCT01693029)
- Testing
- HX575 epoetin alfa, US-licensed epoetin alfa
- Where
- 52 sites in United States
- Volunteers
- 435 people
- Sponsor
- Sandoz
Myelodysplastic Syndromes, Anemia
A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
The purpose of this study is to evaluate the effectiveness of PROCRIT (Epoetin alfa) 80,000 Units given once weekly or 80,000 Units given once every two weeks in anemic patients with Low- or Intermediate-1 risk Myelodysplastic…
- Trial name
- NCT00446602
- Testing
- Epoetin alfa
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Anemia, Iron-Deficiency, Kidney Failure, Chronic
DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)
This study explores the safety and efficacy of intravenous iron therapy in anemic hemodialysis patients treated with epoetin alfa, who have higher serum ferritin levels, but low to normal transferrin saturation.
- Conditions
- Anemia, Iron-Deficiency, Kidney Failure, Chronic, Hemodialysis
- Trial name
- DRIVE (NCT00224081)
- Testing
- Sodium ferric gluconate,
- Where
- 29 sites in United States
- Volunteers
- 134 people
- Sponsor
- Watson Pharmaceuticals
Anemia
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
This single arm study will assess the efficacy and safety of intravenous Mircera, administered with pre-filled syringes, for the treatment of anemia in patients with chronic kidney disease who are on dialysis, and who have…
- Trial name
- NCT00413894
- Testing
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 105 sites in Germany
- Volunteers
- 424 people
- Sponsor
- Hoffmann-La Roche
Myelodysplastic Syndrome
The Role of Erythropoietin in Myelodysplastic Syndrome
The purpose of the study is to elucidate the causative molecular events responsible for the abnormal erythropoiesis in MDS.
- Trial name
- NCT00723112
- Where
- 2 sites in United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- University of Utah
Myelodysplastic Syndromes (MDS)
Evaluation of Response to Biosimilar Erythropoietin Alfa Therapy in Anemic Patients With Myelodysplastic Syndrome
The primary objective of this study is to describe the response to treatment with biosimilar EPO alpha in MDS patients who had already been treated with "originator" EPO alpha and were responsive, and in patients who started…
- Trial name
- NCT06764511
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Anemia
A Study of Monthly Subcutaneous (SC) Mircera for Maintenance Treatment of Participants With Chronic Kidney Disease on Peritoneal Dialysis
This single-arm study will assess the efficacy and safety of monthly administration of SC Mircera for the maintenance of hemoglobin levels in participants with chronic kidney disease on peritoneal dialysis.
- Trial name
- MISTRAL (NCT00737477)
- Testing
- Methoxy polyethylene glycol-epoetin beta
- Where
- 52 sites in France
- Volunteers
- 96 people
- Sponsor
- Hoffmann-La Roche
Left Ventricular Hypertrophy
Left Ventricular Hypertrophy in CKD Patients
The goal of this observational study is to determine the prevalence of left ventricular hypertrophy among patients with chronic kidney disease at Sohag University Hospital and assess the effect of erythropoietin therapy on left…
- Trial name
- NCT07380893
- Testing
- transthoracic echocardiography
- Volunteers
- 100 people
- Sponsor
- Sohag University
Kidney Failure
Effect of Epoetin Beta on Renal Function Within 30 Days Following a Kidney Transplant
Main objective : Assessing the effect of epoetin beta on Hb rate and the glomerular filtration rate estimated 30 days after kidney transplant.
- Trial name
- Neo-PDGF (NCT00815867)
- Testing
- epoetin beta (NeoRecormon ®)
- Where
- 17 sites in France
- Volunteers
- 108 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens